Dewpoint Therapeutics

📍 Boston, United States🗓 Founded 2018👥 147 employees💰 Last funded Jan 2022
Biotechnology Research🌐 dewpointx.com
Website LinkedIn
Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Merck, and Pfizer. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 
5
Total investors
4
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
4
Switzerland
1
Investor activity2018–2022 · investors recorded per year
20182201912020120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Dewpoint Therapeutics?
Dewpoint Therapeutics has 5 investors on record on gritt.io, including 4 early-stage backers, 1 mid-stage.
When did Dewpoint Therapeutics last raise funding?
The most recent investment in Dewpoint Therapeutics recorded on gritt.io was in January 2022.
When was Dewpoint Therapeutics founded?
Dewpoint Therapeutics was founded in 2018.
What industry is Dewpoint Therapeutics in?
Dewpoint Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Dewpoint Therapeutics based?
Dewpoint Therapeutics is headquartered in Boston, United States.